PlainRecalls
FDA Drug Moderate Class II Ongoing

Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02

Reported: November 5, 2025 Initiated: October 15, 2025 #D-0119-2026

Product Description

Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02

Reason for Recall

Lack of Assurance of Sterility

Details

Recalling Firm
ProRx LLC
Units Affected
2,805 vials
Distribution
TX and UT
Location
Exton, PA

Frequently Asked Questions

What product was recalled?
Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02. Recalled by ProRx LLC. Units affected: 2,805 vials.
Why was this product recalled?
Lack of Assurance of Sterility
Which agency issued this recall?
This recall was issued by the FDA Drug on November 5, 2025. Severity: Moderate. Recall number: D-0119-2026.